- Home
- ESPR vs EVGO Comparison
ESPR vs EVGO Comparison
Compare ESPR & EVGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- EVGO
- Stock Information
- Founded
- ESPR 2008
- EVGO 2010
- Country
- ESPR United States
- EVGO United States
- Employees
- ESPR N/A
- EVGO N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- EVGO Other Specialty Stores
- Sector
- ESPR Health Care
- EVGO Consumer Discretionary
- Exchange
- ESPR Nasdaq
- EVGO Nasdaq
- Market Cap
- ESPR 305.0M
- EVGO N/A
- IPO Year
- ESPR 2013
- EVGO N/A
- Fundamental
- Price
- ESPR $1.69
- EVGO $2.76
- Analyst Decision
- ESPR Buy
- EVGO Strong Buy
- Analyst Count
- ESPR 7
- EVGO 10
- Target Price
- ESPR $6.36
- EVGO $6.11
- AVG Volume (30 Days)
- ESPR 4.2M
- EVGO 3.7M
- Earning Date
- ESPR 03-04-2025
- EVGO 03-04-2025
- Dividend Yield
- ESPR N/A
- EVGO N/A
- EPS Growth
- ESPR N/A
- EVGO N/A
- EPS
- ESPR N/A
- EVGO N/A
- Revenue
- ESPR $332,314,000.00
- EVGO $256,825,000.00
- Revenue This Year
- ESPR $5.51
- EVGO $42.11
- Revenue Next Year
- ESPR $1.42
- EVGO $30.36
- P/E Ratio
- ESPR N/A
- EVGO N/A
- Revenue Growth
- ESPR 185.66
- EVGO 59.57
- 52 Week Low
- ESPR $1.47
- EVGO $1.65
- 52 Week High
- ESPR $3.94
- EVGO $9.07
- Technical
- Relative Strength Index (RSI)
- ESPR 49.78
- EVGO 50.16
- Support Level
- ESPR $1.47
- EVGO $2.33
- Resistance Level
- ESPR $1.61
- EVGO $2.82
- Average True Range (ATR)
- ESPR 0.12
- EVGO 0.18
- MACD
- ESPR 0.02
- EVGO 0.07
- Stochastic Oscillator
- ESPR 56.41
- EVGO 90.98
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.